Cochrane · systematic review · CD010253
Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients
Penninga, L, Wettergren, A, Wilson, CH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
T‐cell antibody induction compared to placebo/no intervention for liver transplant recipients
Population: liver transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest T‐cell antibody induction vs placebo/no intervention | RR 0.91 | 16 studies · 1853 participants | Low Downgraded: risk of bias |
Graft loss including death Graft loss including death at latest T‐cell antibody induction vs placebo/no intervention | RR 0.92 | 14 studies · 1749 participants | Low Downgraded: risk of bias |
Acute rejection Number of participants who experienced at least 1 episode with acute rejection at latest T‐cell antibody induction vs placebo/no intervention | RR 0.85 | 16 studies · 1918 participants | Moderate Downgraded: risk of bias |